Compared with the model, CSBTA (75 and 100 mg/kg) significantly reduced liver ALT, AST, Hyp, MDA, TGF-β1, and MMP-9 levels, and up-regulated decreased TP, ALB, SOD contents in the hepatic fibrosis rats. This evidence concerns the gene GPT and Hepatic fibrosis.